



MAIL STOP - PCT
Docket No.: 27578U

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: ROSCHER, et al.

Art Unit: XX

Appl. No.: 10/589,865

Examiner: XX

Appl. Filing Date: August 18, 2006

Confirm. No.: XX

Intl. Appl. No.: PCT/EP2005/050800

Intl. Appl. Filing Date: February 25, 2005

For: **ROFLUMILAST AND GLYCOPYRRONIUM COMBINATION**

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

1. Information Disclosure Statement; and
2. PTO Form-1449 with 43 references cited, and copies of 36 of the 43 references cited.

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.

Respectfully submitted,
NATH & ASSOCIATES PLLC

November 22, 2006


Gary M. Nath, Reg. No. 26,965
Sheldon M. McGee, Reg. No. 50,454
Customer No. 34375

Le



MAIL STOP - PCT
Docket No.: 27578U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: ROSCHER, et al.

Art Unit: XX

Appl. No.: 10/589,865

Examiner: XX

Appl. Filing Date: August 18, 2006

Confirm. No.: XX

Intl. Appl. No.: PCT/EP2005/050800

Intl. Appl. Filing Date: February 25, 2005

For: **ROFLUMILAST AND GLYCOPYRRONIUM COMBINATION**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars: [NOTE: One only of items a, b, c, and d must be checked.]

a. [XXX] The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.

b. [] The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.

The enclosed statement is accompanied by [check one]:

- [] i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or
- [] ii. a check in the amount required by 37 C.F.R. 1.17(p).

c. [] The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311, but before payment of the issue fee.

[] Certification report(e) below; and

[] a check in the amount as required by 1.17(p).

d. [] The enclosed statement is being filed pursuant to 37 C.F.R. 1.97(i), for placement in the file.

e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

[] I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,

or

[] I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

[] Appropriate certification is attached.

f. [XXX] If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

g. [XX] Copies of the documents are attached herewith with a completed PTO Form-1449.

or

[] Copies of the documents are not attached, with a completed PTO Form-1449 as allowed under CFR 1.98 (d) (1) (2). The earlier application is identified as:

and / or

[XXX] Copies of US Patents/Publications not attached, with a completed PTO Form-1449 as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,
NATH & ASSOCIATES PLLC

November 22, 2006


Gary M. Nath, Reg. No. 26,965
Sheldon M. McGee, Reg. No. 50,454
Customer No. 34375

Le

NOV 22 2006

MAIL STOP - PCT
Docket No.: 27578U

PTO FORM-1449

Inventor: ROSCHER, et al.

INFORMATION DISCLOSURE
CITATION

Appl. No.:	Intl. Appl. No:	Art Unit:
10/589,865	PCT/EP2005/050800	XX
Appl. Filing Date:	Intl. Appl. Filing Date:	Examiner:
August 18, 2006	February 25, 2005	XX

U.S. PATENT DOCUMENTS

Exam. Initial	Document No.	Issue/Public. Date	Inventor	Filed Date
	A1 2004/0002548	1/1/2004	Bozung et al.	6/27/2003
	A2 5,712,298 (corresp. to WO9501338)	1/27/1998	Amschler	7/2/1994
	A3 6,302,331	10/16/2001	Dvorsky et al.	4/20/2000
	A4 6,204,285	3/20/2001	Fabiano et al.	6/27/1997
	A5 6,454,193	9/24/2002	Busick et al.	4/20/2000
	A6 6,397,838	6/4/2002	Zimlich Jr. et al.	12/21/1999
	A7 2006/0069073 (corresp. to WO2006003078)	3/30/2006	Pieper et al.	6/27/2005

FOREIGN PATENT DOCUMENTS

Exam. Initial	Document No.	Public. Date	Country	Translation
	A8 0 407 028 B2	1/9/1991	EP	N/A
	A9 02/096463 A1	12/5/2002	WO	N/A
	A10 03/011274 A2	2/13/2003	WO	N/A
	A11 93/11743 A1	6/24/1993	WO	N/A
	A12 02/096423 A2	12/5/2002	WO	N/A
	A13 95/02650 A1	1/26/1995	WO	N/A
	A14 02/069945 A2	9/12/2002	WO	Abstract
	A15 2005/074983 A2	8/18/2005	WO	N/A
	A16 2006/008213 A1	1/26/2006	WO	N/A
	A17 95/01338 A1	1/12/1995	WO	Abstract
	A18 0 725 725 B1	8/14/1996	EP	N/A
	A19 0 505 321 A2	9/23/1992	EP	No
	A20 100 61 137 A1	6/20/2002	DE	Abstract
	A21 2006/003078 A2	1/12/2006	WO	No
	A22 91/11495 A1	8/8/1991	WO	Abstract
	A23 91/14422 A1	10/3/1991	WO	N/A
	A24 91/04011 A1	4/4/1991	WO	N/A
	A25 91/11173 A1	8/8/1991	WO	N/A
	A26 0 372 777 B1	6/13/1990	EP	N/A
	A27 98/00133 A1	1/8/1998	WO	N/A
	A28 98/21183 A1	5/22/1998	WO	Abstract
	A29 98/00132 A1	1/8/1998	WO	N/A
	A30 01/76575 A2	10/18/2001	WO	N/A
	A31 02/30394 A2	4/18/2002	WO	N/A
	A32 1 369 129 A1	12/10/2003	EP	N/A
	A33 0 691 865 B1	1/17/1996	EP	N/A
	A34 0 650 410 B1	5/3/1995	EP	N/A
	A35 00/69468 A1	11/23/2000	WO	Abstract
	A36 92/11190 A2	7/9/1992	WO	N/A
	A37 96/32150 A1	10/17/1996	WO	N/A
	A38 00/07567 A1	2/17/2000	WO	Abstract
	A39 0 553 298 B1	8/4/1993	EP	N/A
	A40			
	A41			
	A42			
	A43			

NOV 22 2006

MAIL STOP - PCT
Docket No.: 27578U

OTHER

(Including Author, Title, Date, Pertinent Pages, etc.)

PATENT & TRADEMARK OFFICE

Exam. Initial	OTHER	
A44	Mirakhur, R.K., et al., "Glycopyrrolate: pharmacology and clinical use", <u>Anaesthesia</u> , Vol. 38, pg. 1195-1204, (1983).	
A45	Levin, R.M., et al., "Direct Measurement of the Anticholinergic Activity of a Series of Pharmacological Compounds on the Canine and Rabbit Urinary Bladder", <u>The Journal of Urology</u> , Vol. 128, pg. 396-398, (1982).	
A46	Cooke, R.D., "Glycopyrrolate in bladder dysfunction", <u>SA Medical Journal</u> , Vol. 63, pg. 3, (1983).	
A47	Demian, J., et al., "High-Performance Liquid Chromatographic Separation of 3-[(Cyclopentylhydroxyphenyl-acetyl)oxy]-1,1-Dimethyl-pyrrolidinium Bromide Diastereomers", <u>Journal of Liquid Chromatography</u> , Vol. 13, No. 4, pg. 779-787, (1990).	
Examiner		Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP' 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.